UHTR

Beiträge: 5
Zugriffe: 5.918 / Heute: 1
Utd. Therapeutics 233,86 $ -0,89% Perf. seit Threadbeginn:   +35,21%
 
UHTR Tamakoschy
Tamakoschy:

UHTR

2
28.03.15 17:48
#1
seekingalpha.com/article/...on-good-news-why-i-bought-that-dip
www.unither.com

Werbung

Entdecke die beliebtesten ETFs von SPDR

SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +37,75%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +37,68%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +37,07%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +36,39%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +31,25%

UHTR Tamakoschy
Tamakoschy:

United Therapeutics Corporation

 
29.03.15 21:28
#2
www.unither.com
financials.morningstar.com/ratios/r.html?t=UTHR
markets.ft.com/research/Markets/Tearsheets/Forecasts?…
www.macroaxis.com/invest/compare/UTHR

Kurzporträt



Logo United Therapeutics Corpor
Develops pharmaceutical products

United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

The company operates in two business segments: Pharmaceuticals and Telemedicine.

Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

de.4-traders.com/UNITED-THERAPEUTICS-CORPO-11262/fundamentals/
UHTR Balu4u
Balu4u:

Gewinn im Quartal verdoppelt

 
27.01.20 20:23
#3
www.analystratings.com/articles/...a-buy-rating-from-wedbush/
UHTR Balu4u
Balu4u:

3tes Buy rating

 
03.02.20 19:51
#4
www.analystratings.com/articles/...ed-its-third-buy-in-a-row/
UHTR Vassago

UTHR 228$

 
#5
  • Dr. Reddy's kündigt die Einführung der Treprostinil Injektion an, einer therapeutischen äquivalenten generischen Version von Remodulin (Treprostinil) Injektion

www.sec.gov/Archives/edgar/data/1135951/...drr0473_ex99-1.htm
Remodulin ist UTHR's zweitstärkstes Produkt, gemessen am Umsatz von 500 Mio. $ in 2022



Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem United Therapeutics Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
2 4 UHTR Tamakoschy Vassago 21.04.23 15:35

--button_text--